Parkinson’s drug generates disease stabilization and, with the country’s autonomy in its production, it will be more accessible
Parkinson’s affects more than 200,000 Brazilians, according to the Ministry of Health. With this scenario, the Oswaldo Cruz Foundation (Fiocruz) announced, this Wednesday, 30, an important news for Brazil: the country’s autonomy for the production of the drug Pramipexole against Parkinson’sthrough the Productive Development Partnership (PDP).
DRUG AGAINST PARKINSON STABILIZES THE DISEASE
The access of Parkinson’s patients to this drug could be expanded with the project. “This PDP brought many benefits, both in technology and in the expansion of access to cutting-edge treatment for SUS users affected by this disease”said the director of Farmanguinhos/Fiocruz, Jorge Mendonça.
Pramipexole acts in the stabilization of the disease, offering a better quality of life to the patient. According to data from the Ministry of Health, there are more than 1.5 million family members, professionals and friends who care for people with Parkinson’s. the chronic disease degenerates the central nervous system, causing damage to its functioning, which leads to problems with movement, tremors, muscle stiffness and speech disorders.
“The nationalization of this Active Pharmaceutical Ingredient (IFA) by a national pharmochemical guarantees the supply of a quality product, following Anvisa’s sanitary rules, strengthening our technology absorption capacity and generating employment and qualified labor in Brazil”added Mendonça.
Source: Recreio
